{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:22:04Z","timestamp":1789122124076,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["No. 2024JJ5478"],"award-info":[{"award-number":["No. 2024JJ5478"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["No. 2024JJ5498"],"award-info":[{"award-number":["No. 2024JJ5498"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Guangxi Zhuang Autonomous Region","award":["No. 2024JJA140129"],"award-info":[{"award-number":["No. 2024JJA140129"]}]},{"name":"the Scientific Research Project of Hunan Provincial Health Commission","award":["No. W20243217"],"award-info":[{"award-number":["No. W20243217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57652-6","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:16:30Z","timestamp":1782472590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1\/2 variants in breast cancer: a retrospective cohort of 265 patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Feifei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"57652_CR1","first-page":"229","volume":"263","author":"Bray","year":"2024","unstructured":"Bray, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 263, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"57652_CR2","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson, L. & Gathani, T. Understanding breast cancer as a global health concern. Br. J. Radiol. 95, 20211033 (2022).","journal-title":"Br. J. Radiol."},{"key":"57652_CR3","first-page":"2929","volume":"5","author":"X Dai","year":"2015","unstructured":"Dai, X. et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am. J. Cancer Res. 5, 2929\u20132943 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"57652_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3343\/alm.2020.40.2.114","volume":"40","author":"A Lee","year":"2020","unstructured":"Lee, A., Moon, B. I. & Kim, T. H. BRCA1\/BRCA2 pathogenic variant breast cancer: Treatment and prevention strategies. Ann. Lab. Med. 40, 114\u2013121 (2020).","journal-title":"Ann. Lab. Med."},{"key":"57652_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12371","volume":"10","author":"J Cortes","year":"2024","unstructured":"Cortes, J. et al. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119. J. Pathol. Clin. Res. 10, e12371 (2024).","journal-title":"J. Pathol. Clin. Res."},{"key":"57652_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/oncolo\/oyad309","volume":"29","author":"G Dajti","year":"2024","unstructured":"Dajti, G. et al. Prognostic role of p53 immunohistochemical status in invasive breast cancer: A retrospective review of 1387 cases with luminal-like\/Her2 negative breast tumors. Oncologist 29, 384\u2013391 (2024).","journal-title":"Oncologist"},{"key":"57652_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559\u2013569 (2019).","journal-title":"J. Clin. Oncol."},{"key":"57652_CR8","doi-asserted-by":"crossref","unstructured":"Yoshimura, A., Imoto, I. & Iwata, H. Functions of breast cancer predisposition genes: Implications for clinical management. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23137481"},{"key":"57652_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"R Hong","year":"2022","unstructured":"Hong, R. & Xu, B. Breast cancer: An up-to-date review and future perspectives. Cancer Commun. (Lond) 42, 913\u2013936 (2022).","journal-title":"Cancer Commun. (Lond)"},{"key":"57652_CR10","doi-asserted-by":"crossref","unstructured":"Palleschi, M. et al. Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants. Oncologist 30 (2025).","DOI":"10.1093\/oncolo\/oyaf052"},{"key":"57652_CR11","doi-asserted-by":"crossref","unstructured":"Gurioli, G. et al. Clinical impact of next-generation sequencing multi-gene panel highlighting the landscape of germline alterations in ovarian cancer patients. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms232415789"},{"key":"57652_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","volume":"6","author":"E Pohl-Rescigno","year":"2020","unstructured":"Pohl-Rescigno, E. et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: A secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncol. 6, 744\u2013748 (2020).","journal-title":"JAMA Oncol."},{"key":"57652_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King, M. C., Marks, J. H. & Mandell, J. B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643\u2013646 (2003).","journal-title":"Science"},{"key":"57652_CR14","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"57652_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","volume":"948","author":"JD Fackenthal","year":"2007","unstructured":"Fackenthal, J. D. & Olopade,. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 948, 937\u2013948 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"57652_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso, G., Weroha, S. J. & Cliby, W. Ovarian cancer: A review. JAMA 334, 1278\u20131291 (2025).","journal-title":"JAMA"},{"key":"57652_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/10408363.2023.2234488","volume":"60","author":"G Ponti","year":"2023","unstructured":"Ponti, G. et al. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies. Crit. Rev. Clin. Lab. Sci. 60, 640\u2013650 (2023).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"57652_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 7, a016600 (2015).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"57652_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243\u2013254 (2010).","journal-title":"Cell"},{"key":"57652_CR20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/humu.23965","volume":"41","author":"X Gao","year":"2020","unstructured":"Gao, X. et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Hum. Mutat. 41, 696\u2013708 (2020).","journal-title":"Hum. Mutat."},{"key":"57652_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","volume":"27","author":"C Winter","year":"2016","unstructured":"Winter, C. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann. Oncol. 27, 1532\u20131538 (2016).","journal-title":"Ann. Oncol."},{"key":"57652_CR22","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.18632\/aging.202724","volume":"13","author":"F Shao","year":"2021","unstructured":"Shao, F. et al. PARP inhibitors in breast and ovarian cancer with BRCA mutations: A meta-analysis of survival. Aging (Albany NY) 13, 8975\u20138988 (2021).","journal-title":"Aging (Albany NY)"},{"key":"57652_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.breast.2022.08.012","volume":"66","author":"X Jia","year":"2022","unstructured":"Jia, X. et al. A systematic review and meta-analysis of BRCA1\/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer. Breast 66, 31\u201339 (2022).","journal-title":"Breast"},{"key":"57652_CR24","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","volume":"30","author":"DL Richardson","year":"2024","unstructured":"Richardson, D. L. et al. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice. Clin. Cancer Res. 30, 4644\u20134653 (2024).","journal-title":"Clin. Cancer Res."},{"key":"57652_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13048-023-01283-2","volume":"16","author":"Y Ma","year":"2023","unstructured":"Ma, Y. et al. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1\/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. J. Ovarian Res. 16, 209 (2023).","journal-title":"J. Ovarian Res."},{"key":"57652_CR26","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"57652_CR27","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/ijc.35313","volume":"156","author":"X Xie","year":"2025","unstructured":"Xie, X. et al. Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer treatment: A systematic review and meta analysis. Int. J. Cancer 156, 1936\u20131949 (2025).","journal-title":"Int. J. Cancer"},{"key":"57652_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"57652_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66\u201371 (1994).","journal-title":"Science"},{"key":"57652_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789\u2013792 (1995).","journal-title":"Nature"},{"key":"57652_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/pjp.2024.135703","volume":"7","author":"N Eras","year":"2024","unstructured":"Eras, N., Tuncel, F., Alt\u0131ntas, Z. & Erden,. Clinicopathological characteristics and BRCA1\/BRCA2 pathogenic variants of patients with breast cancer. Pol. J. Pathol. 7, 1\u20137 (2024).","journal-title":"Pol. J. Pathol."},{"key":"57652_CR32","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.5858\/134.7.e48","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48-72 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"57652_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen, T. O. et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J. Natl. Cancer Inst. 113, 808\u2013819 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"57652_CR34","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"57652_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"57652_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"57652_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"57652_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104109","volume":"190","author":"E Zattarin","year":"2023","unstructured":"Zattarin, E. et al. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities. Crit. Rev. Oncol. Hematol. 190, 104109 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"57652_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12885-024-12089-w","volume":"24","author":"Z Wu","year":"2024","unstructured":"Wu, Z. et al. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: Experience from a clinical diagnostic center from greater Shanghai area. BMC Cancer 24, 411 (2024).","journal-title":"BMC Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57652-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:18:17Z","timestamp":1789118297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57652-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57652"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57652-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Study protocols described above comply with the ethical requirements of The Second Xiangya Hospital\n                      .","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"28460"}}